Mexico - Delayed Quote MXN

WisdomTree Issuer ICAV - Artificial Intelligence Ucits Fund (WTAIN.MX)

1,103.61

0.00

(0.00%)

At close: April 23 at 12:54:56 PM CST

Hims & Hers Health Inc (HIMS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

Hims & Hers Health Inc (HIMS) reports a 111% revenue surge and outlines future growth strategies amid expanding service offerings and strategic partnerships.

GuruFocus.com 3 hours ago

NVO
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.

Zacks 21 hours ago

ACAD

NVO

DNLI
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks 21 hours ago

NVO
FDA accepts Novo Nordisk’s NDA submission for weight management therapy

The agency’s decision on the NDA is expected in the fourth quarter of this year.

Pharmaceutical Technology yesterday

NVO
With compounders out of the way, Lilly and Novo go after each other

The two obesity leaders are pulling on all levers to stay on top of the market.

Pharma Voice yesterday

LLY

CVS

NVO
Is Novo Nordisk A/S (NVO) The Best Stock to Buy and Hold For 10 Years?

We recently compiled a list of the 12 Best Stocks to Buy and Hold For 10 Years. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks to buy and hold for 10 years. When the stock market experiences a sharp decline, as it […]

Insider Monkey yesterday

NVO
What is CVS? 'We are ... working through that very question'

CVS Health is working to balance all parts of its vertically integrated business under new leadership. CEO David Joyner tells Yahoo Finance he's working to define the company.

Yahoo Finance yesterday

LLY

CVS

NONOF
Why Hims & Hers Health, Inc. (HIMS) Soared Last Week

We recently published a list of These 10 Firms Soared Last Week, Here’s Why. In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against other firms that soared last week. The past trading week saw a more calm, generally optimistic, market environment amid the temporary pause […]

Insider Monkey 2 days ago

NVO
Why Hims & Hers Health, Inc. (HIMS) Went Up On Friday

We recently published a list of What Propelled These 10 Firms’ Double-Digit Gains? In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against other Friday’s top performers. The stock market ended the trading week on a strong note, with all major indices clocking in strong gains, as […]

Insider Monkey 3 days ago

NVO
Novo Nordisk shares jump as FDA accepts oral Wegovy application

Investing.com -- Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy. If approved, the pill formulation would be the first oral GLP-1 treatment for chronic weight management in adults with obesity or overweight conditions.

Investing.com 3 days ago

NVO

LLY
US FDA accepts Novo Nordisk's application for oral Wegovy for weight loss

The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved. U.S.-listed shares of Novo added to session gains and were last up 5.72% at $69.36 following the news. Novo Nordisk's oral GLP-1 drug Rybelsus, which also has the same active ingredient semaglutide, is already approved for blood sugar control in adults with diabetes.

Reuters 3 days ago

NVO

LLY
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.

Motley Fool 3 days ago

LLY

NVO

VKTX
Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why.

Analysts were rushing to reiterate their conviction in the stock following Thursday’s blow to Zepbound and Lilly shares.

Barrons.com 3 days ago

LLY

CVS

NVO
Eli Lilly stock sell-off was 'overreaction': Analysts

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an overreaction to GLP-1 news.

Yahoo Finance 3 days ago

NONOF

NVO

CVS
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?

Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks 3 days ago

NVO
Update: Eli Lilly Brushes Off CVS Decision to Drop Zepbound Coverage

(Updates with CVS Health's response in the third and fourth paragraphs and latest stock moves in the

PREMIUM
MT Newswires 3 days ago

CVS

LLY

NVO
Stocks to watch this week: Palantir, TSMC, Novo Nordisk and JD Wetherspoon

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK yesterday

ARM

NXGPF

NXGPY
Is Novo Nordisk Stock a Buy?

The market for weight loss drugs is white-hot, and competition is heating up fast. This Danish company is already facing a powerful rival in this growing segment. For years, Denmark-based Novo Nordisk (NYSE: NVO) was a fairly traditional develop-and-market pharmaceutical company that escaped notice by many investors.

Motley Fool 3 days ago

NVO

LLY

VKTX
Q1 2025 CVS Health Corp Earnings Call

Q1 2025 CVS Health Corp Earnings Call

Thomson Reuters StreetEvents 4 days ago

CVS

NVO
CVS stock reacts to full-year guidance, Novo Nordisk GLP-1 deal

CVS Health (CVS) is maintaining Thursday gains ahead of the closing bell after outpacing top and bottom line expectations, paired with a positive full-year outlook for 2025. Yahoo Finance senior health reporter Anjalee Khemlani joins the Market Domination in breaking down the pharmacy chain's reaction to Medicare Advantage costs and its formulary deal with GLP-1 weight-loss drug developer Novo Nordisk (NVO). She highlights comments from CVS CEO David Joyner on the Novo Nordisk deal. Jefferies equity research analyst Brian Tanquilut explained to Yahoo Finance why it is looking like a "new day" for CVS on these earnings and guidance prints. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 4 days ago

NONOF

NVO

CVS

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

WisdomTree Issuer ICAV - Artificial Intelligence Ucits Fund (WTAIN.MX)

Related ETF News

Hims & Hers Health Inc (HIMS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

FDA accepts Novo Nordisk’s NDA submission for weight management therapy

With compounders out of the way, Lilly and Novo go after each other

Is Novo Nordisk A/S (NVO) The Best Stock to Buy and Hold For 10 Years?

What is CVS? 'We are ... working through that very question'

Why Hims & Hers Health, Inc. (HIMS) Soared Last Week

Why Hims & Hers Health, Inc. (HIMS) Went Up On Friday

Novo Nordisk shares jump as FDA accepts oral Wegovy application

US FDA accepts Novo Nordisk's application for oral Wegovy for weight loss

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why.

Eli Lilly stock sell-off was 'overreaction': Analysts

Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?

Update: Eli Lilly Brushes Off CVS Decision to Drop Zepbound Coverage

Stocks to watch this week: Palantir, TSMC, Novo Nordisk and JD Wetherspoon

Is Novo Nordisk Stock a Buy?

Q1 2025 CVS Health Corp Earnings Call

CVS stock reacts to full-year guidance, Novo Nordisk GLP-1 deal